for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jiangsu Hengrui Medicine Co Ltd

600276.SS

Latest Trade

86.12CNY

Change

-0.79(-0.91%)

Volume

32,883,846

Today's Range

85.00

 - 

87.00

52 Week Range

64.32

 - 

105.00

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
86.91
Open
86.91
Volume
32,883,846
3M AVG Volume
427.77
Today's High
87.00
Today's Low
85.00
52 Week High
105.00
52 Week Low
64.32
Shares Out (MIL)
5,331.72
Market Cap (MIL)
463,379.50
Forward P/E
70.67
Dividend (Yield %)
0.22

Next Event

Q4 2020 Jiangsu Hengrui Medicine Co Ltd Earnings Release

Latest Developments

More

Jiangsu Hengrui Medicine Says 9-Month Net Profit Up 14.0% Y/Y

Jiangsu Hengrui Medicine's H1 Net Profit Up 10.3% Y/Y

Jiangsu Hengrui Medicine's Q1 Net Profit Up 10.3% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jiangsu Hengrui Medicine Co Ltd

JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.7 Kunlunshan Road

Lianyungang Eco & Tech Development Zone

LIANYUNGANG, JNG

222000

China

+86.518.81220983

http://www.hrs.com.cn

Executive Leadership

Yunshu Zhou

Chairman of the Board, General Manager

Song Zhou

Chief Financial Officer

Hongbin Dai

Deputy General Manager, Director

Jieping Sun

Deputy General Manager, Director

Lianshan Zhang

Deputy General Manager, Director

Key Stats

1.77 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

13.8K

2018

17.4K

2019

23.3K

2020(E)

28.8K
EPS (CNY)

2017

0.607

2018

0.764

2019

1.004

2020(E)

1.229
Price To Earnings (TTM)
68.87
Price To Sales (TTM)
17.99
Price To Book (MRQ)
13.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
22.56
Return on Equity (TTM)
19.96

Latest News

Latest News

BRIEF-Jiangsu Hengrui Medicine's Q1 Net Profit Up 10.3% Y/Y

* SAYS Q1 NET PROFIT UP 10.3% Y/Y AT 1.3 BILLION YUAN ($183.65 million) Source text in Chinese: https://bit.ly/3aBqoIQ Further company coverage: ($1 = 7.0785 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Jiangsu Hengrui Medicine's 2019 Net Profit Up 31.1% Y/Y

* SAYS 2019 NET PROFIT UP 31.1% Y/Y AT 5.3 BILLION YUAN ($747.00 million) Source text in Chinese: https://bit.ly/3ae0tHY Further company coverage: ($1 = 7.0950 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration

BRIEF-Jiangsu Hengrui Medicine receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

* Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up